Long-term Effects of Weight-Reducing Interventions in Hypertensive Patients&lt;subtitle&gt;Systematic Review and Meta-analysis&lt;/subtitle&gt;

Horvath, Karl; Jeitler, Klaus; Siering, Ulrich; Stich, Anne Kathrin; Skipka, Guido; Gratzer, Thomas W; Siebenhofer, Andrea

doi:10.1001/archinte.168.6.571

Cited by 120 publications

(86 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[59] Patients assigned to weight loss diets, orlistat, or sibutramine reduced their body weight more effectively than did patients in the usual care/placebo groups. Reduction of BP was higher in patients treated with weight loss diets or orlistat than with sibutramine.…”

Section: Sibutramine and Sympathetic Nervous System Blood Pressurementioning

confidence: 97%

“…[57] Indeed, because of its mode of action, sibutramine treatment could somewhat dampen the classically observed reduction in arterial BP resulting from weight loss as shown in several meta-analyses. [50,53,[58][59][60] In a meta-analysis of 21 double-blind, randomised controlled trials of sibutramine, modest increases in systolic and diastolic BP were observed in patients treated with sibitramine as compared to placebo. [58] These results were confirmed in another meta-analysis of seven long-term studies.…”

Section: Sibutramine and Sympathetic Nervous System Blood Pressurementioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular Risk-Benefit Profile of Sibutramine

Scheen

2010

American Journal Cardiovascular Drugs

View full text Add to dashboard Cite

SUMMARYSibutramine is a combined norepinephrine and serotonin reuptake inhibitor used as an antiobesity agent to reduce appetite and promote weight loss in combination with diet and exercise. At a daily dose of 10-20 mg, it was initially considered to have a good safety profile as it does not induce primary pulmonary hypertension or adverse effects on cardiac valves, in contrast to what was previously reported with some other anti-obesity agents. However, it exerts

show abstract

Section: Sibutramine and Sympathetic Nervous System Blood Pressurementioning

confidence: 97%

Section: Sibutramine and Sympathetic Nervous System Blood Pressurementioning

confidence: 99%

Cardiovascular Risk-Benefit Profile of Sibutramine

Scheen

2010

American Journal Cardiovascular Drugs

View full text Add to dashboard Cite

show abstract

“…Recently, in March 2008, a systematic review 31 on obese patients with essential hypertension who received calorie-restricted diets or orlistat or sibutramine was published. All the groups were compared with placebo control groups.…”

Section: Body Mass Index (Bmi)mentioning

confidence: 99%

Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis

2008

View full text Add to dashboard Cite

CONTEXT: Systemic arterial hypertension is part of the metabolic syndrome resulting from obesity. OBJECTIVE:To evaluate the effect of sibutramine on overweight and obese patients' blood pressure through a systematic review. METHODS:All the studies included needed to be randomized controlled trials. The methodological quality of the selected trials was assessed using the criteria described in the Cochrane Handbook. The participants were overweight and obese patients; the intervention was sibutramine compared with placebo. The primary outcome measurement was systolic and diastolic blood pressure and the secondary measurement was blood pressure. Studies were identified by searching the following sources: Literatura LatinoAmericana e do Caribe em Ciências da Saúde (Lilacs), Medline, Cochrane reviews, manual searches, personal communication and contact with the pharmaceutical industry. There were no language, date or other restrictions. Data collection and extraction was performed by two reviewers, who independently obtained the full articles of all eligible papers.RESULTS: Three meta-analyses were produced: 1) systolic blood pressure outcome (eight studies) did not show statistical signifi cance between sibutramine and placebo: weighted mean difference (WMD) 1.57, confi dence interval (CI) -0.03 to 3.18; 2) diastolic blood pressure outcome (ten studies) did not show statistical signifi cance between sibutramine and placebo: WMD 1.13, CI -0.49 to 2.76; 3) blood pressure outcome (two studies) also did not show statistical signifi cance between the groups: relative risk (RR) 0.69, CI 0.07 to 7.01. CONCLUSIONS:The meta-analyses presented in this systematic review show that sibutramine does not have a statistically signifi cant effect on blood pressure, compared with placebo.

show abstract

“…150 In a recent meta-analysis of sibutramine studies in hypertensive patients, sibutramine reduced body weight by 3.7 kg more than placebo. 154 Subgroup analyses in other meta-analyses suggested that weight loss with sibutramine is similar in hypertensive and normotensive obese patients. 34,64 Even though sibutramine increased BP when given to hypertensive patients, [150][151][152] it did not compromise BP control when hypertension was well controlled with angiotensin-converting enzyme inhibitors, 151 calcium channel blockers, 150 or beta blockers.…”

Section: Safety Considerationsmentioning

confidence: 98%

The use of sibutramine in the management of obesity and related disorders: An update

Tzotzas¹,

Krassas²,

Τζιόμαλος³

et al. 2009

VHRM

View full text Add to dashboard Cite

Aims:To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders. Methods and results:The most important articles on sibutramine up to January 2009 were located by a PubMed and Medline search. Sibutramine reduces food intake and body weight more than placebo and has positive effects on the lipid profile (mainly triglycerides and high density lipoprotein cholesterol), glycemic control and inflammatory markers in studies for up to one year. Preliminary studies showed that sibutramine may also improve other obesityassociated disorders such as polycystic ovary syndrome, left ventricular hypertrophy, binge eating disorder and adolescent obesity. The high discontinuation rates and some safety issues mainly due to the increase in blood pressure and pulse rate have to be considered. Additionally, it has not yet been established that treatment with sibutramine will reduce cardiovascular events and total mortality. Conclusions: Sibutramine, in conjunction with lifestyle measures, is a useful drug for reducing body weight and improving associated cardiometabolic risk factors and obesity-related disorders. Studies of longer duration are required to determine the precise indications of the drug, to evaluate safety issues and to assess its efficacy on cardiovascular mortality.

show abstract

Long-term Effects of Weight-Reducing Interventions in Hypertensive Patients<subtitle>Systematic Review and Meta-analysis</subtitle>

Cited by 120 publications

References 54 publications

Cardiovascular Risk-Benefit Profile of Sibutramine

Cardiovascular Risk-Benefit Profile of Sibutramine

Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis

The use of sibutramine in the management of obesity and related disorders: An update

Contact Info

Product

Resources

About